These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11879274)

  • 1. New advances in the management of cutaneous T-cell lymphoma.
    Young SK
    Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
    [No Abstract]   [Full Text] [Related]  

  • 2. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Foss F; Demierre MF; DiVenuti G
    Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denileukin diftitox and vision loss.
    Ruddle JB; Prince HM
    Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
    [No Abstract]   [Full Text] [Related]  

  • 6. Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
    Liu HL; Kim YH
    Arch Dermatol; 2002 Mar; 138(3):398-9. PubMed ID: 11902993
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
    Park M; Liu GT; Piltz-Seymour J; Wisda CL; Rook AH; Junkins-Hopkins JM; Nasta SD; Kim EJ
    Leuk Lymphoma; 2007 Apr; 48(4):808-11. PubMed ID: 17454642
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical and oral bexarotene.
    Schadt CR
    Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell lymphoma products.
    Bell TJ
    Nurse Pract; 2001 Mar; 26(3):19. PubMed ID: 11270155
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.
    Dao H; Barr PM; Honda K
    J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
    Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
    Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
    McCann S; Akilov OE; Geskin L
    Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
    J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.